CCM
NAGE

Chilton Capital Management’s Niagen Bioscience NAGE Stock Holding History

Chilton Capital Management’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,667
Closed -$6K – 632
2021
Q4 		$6K Buy
+1,667
New +$9K ﹤0.01% 547

Other funds holding NAGE

YRHAM
Yong Rong (HK) Asset Management Sheung Wan, Hong Kong $227M AUM 300.38% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tieton Capital Management Yakima, Washington $299M AUM 54.55% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Chilton Capital Management's NAGE Position: Q1 2022 in Review

Chilton Capital Management sold out of Niagen Bioscience (NAGE) in Q1 2022, closing a stake of 1,667 shares — an estimated $6K sold.

Chilton Capital Management first reported a position in NAGE in Q4 2021 and held it in 1 quarter. The position peaked at $6K in Q4 2021. 82 funds tracked by Wall St. Rank hold NAGE as of Q1 2022.

  • Chilton Capital Management reported no remaining Niagen Bioscience position as of Q1 2022 after selling out during the quarter.
  • Chilton Capital Management sold 1,667 Niagen Bioscience shares in Q1 2022, an estimated $6K.
  • Chilton Capital Management first reported a position in Niagen Bioscience in Q4 2021 and held it in 1 quarter.
  • Chilton Capital Management's Niagen Bioscience position peaked at $6K in Q4 2021.
  • 82 funds tracked by Wall St. Rank held Niagen Bioscience as of Q1 2022.

Based on Chilton Capital Management's 13F filing for Q1 2022, filed 16 May 2022.